Broad-spectrum semi-synthetic carbapenem antibiotic; first stable derivative of thienamycin, q.v. Prepn: W. J. Leanza et al., J. Med. Chem. 22, 1435 (1979); B. G. Christensen et al., BE 848545; eidem, US 4194047 (1977, 1980 both to Merck & Co.); of crystalline form: T. W. Miller, EP 6639; eidem, US 4260543 (1980, 1981 both to Merck & Co.). Total synthesis without formation of thienamycin: I. Shinkai et al., Tetrahedron Lett. 23, 4903 (1982). Antimicrobial activity: S. Ishihara et al., Int. J. Antimicrob. Agents 19, 565 (2002). HPLC determn in serum: C. M. Myers, J. L. Blumer, Antimicrob. Agents Chemother. 26, 78 (1984); in pharmaceutical formulations: R. J. Forsyth, D. P. Ip, J. Pharm. Biomed. Anal. 12, 1243 (1994). Pharmacokinetics in dogs: C. W. Barker et al., Am. J. Vet. Res. 64, 694 (2003). Series of articles on in vitro activity, pharmacokinetics, clinical efficacy of combination with cilastatin sodium, q.v., a renal dehydropeptidase I inhibitor: J. Antimicrob. Chemother. 12, Suppl. D, 1-155 (1983); Rev. Infect. Dis. 7, Suppl. 3, S389-S536 (1985); Am. J. Med. 78, Suppl. 6A, 1-167 (1985). Comprehensive description: E. R. Oberholtzer, Anal. Profiles Drug Subs. 17, 73-114 (1988); M. M. Buckley et al., Drugs 44, 408-444 (1992).
Antibacterial.
Antibacterial (Antibiotics); β-Lactams; Carbapenems